A Phase 2B Randomized Double Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection as Adjunct to Revascularization of Infrapopliteal Lesions in Subjects With Advanced Peripheral Artery Disease and Tissue Loss
Latest Information Update: 06 Nov 2021
At a glance
- Drugs JVS 100 (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms STOP-PAD
- Sponsors Juventas Therapeutics
- 01 Aug 2020 Status changed to completed, according to results published in the Journal of Endovascular Therapy
- 04 Feb 2016 According to a Juventas therapeutics media release, first patient is enrolled in the phase II study of JVS-100 for the of Advanced Peripheral Artery Disease
- 08 Dec 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.